Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below 50-Day Moving Average – Should You Sell?

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s stock price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $3.92 and traded as low as $3.80. Voyager Therapeutics shares last traded at $3.96, with a volume of 462,509 shares traded.

Analyst Ratings Changes

VYGR has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Voyager Therapeutics in a report on Tuesday, March 17th. Truist Financial upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Performance

The company’s fifty day simple moving average is $3.92 and its two-hundred day simple moving average is $4.19. The company has a market capitalization of $236.02 million, a price-to-earnings ratio of -1.95 and a beta of 1.38.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.08. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. The business had revenue of $13.46 million for the quarter, compared to analyst estimates of $10.49 million. Sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the sale, the chief executive officer owned 484,060 shares in the company, valued at $1,834,587.40. This represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 49,783 shares of company stock worth $188,694 in the last 90 days. Corporate insiders own 6.39% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VYGR. AQR Capital Management LLC raised its position in shares of Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after acquiring an additional 317,927 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Voyager Therapeutics during the first quarter valued at $218,000. Acadian Asset Management LLC increased its stake in Voyager Therapeutics by 863.3% during the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock worth $3,474,000 after purchasing an additional 11,929 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of Voyager Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after purchasing an additional 6,748 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.